Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. more
Time Frame | RCEL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.22% | -3.39% | 0.2% |
1-Month Return | 0.72% | -1.92% | 2.72% |
3-Month Return | 22.03% | -10.54% | 7.31% |
6-Month Return | 54% | -4.47% | 10.44% |
1-Year Return | 1.21% | 4.06% | 27.53% |
3-Year Return | 2.62% | 0.94% | 30.88% |
5-Year Return | -69.9% | 36.67% | 89.21% |
10-Year Return | 97.17% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 5.40M | 5.40M | 14.26M | 50.56M | 50.14M | [{"date":"2019-12-31","value":10.67,"profit":true},{"date":"2020-12-31","value":10.67,"profit":true},{"date":"2021-12-31","value":28.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.17,"profit":true}] |
Cost of Revenue | 1.19M | 1.19M | 2.97M | 8.87M | 7.78M | [{"date":"2019-12-31","value":13.4,"profit":true},{"date":"2020-12-31","value":13.4,"profit":true},{"date":"2021-12-31","value":33.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":87.68,"profit":true}] |
Gross Profit | 4.21M | 4.21M | 11.29M | 41.69M | 42.36M | [{"date":"2019-12-31","value":9.93,"profit":true},{"date":"2020-12-31","value":9.93,"profit":true},{"date":"2021-12-31","value":26.65,"profit":true},{"date":"2022-12-31","value":98.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 77.97% | 77.97% | 79.16% | 82.45% | 84.48% | [{"date":"2019-12-31","value":92.28,"profit":true},{"date":"2020-12-31","value":92.28,"profit":true},{"date":"2021-12-31","value":93.69,"profit":true},{"date":"2022-12-31","value":97.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 29.25M | 29.25M | 53.97M | 80.78M | 92.80M | [{"date":"2019-12-31","value":31.52,"profit":true},{"date":"2020-12-31","value":31.52,"profit":true},{"date":"2021-12-31","value":58.16,"profit":true},{"date":"2022-12-31","value":87.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (24.72M) | (24.72M) | (42.68M) | (40.40M) | (42.66M) | [{"date":"2019-12-31","value":-2472359092,"profit":false},{"date":"2020-12-31","value":-2472359092,"profit":false},{"date":"2021-12-31","value":-4267900000,"profit":false},{"date":"2022-12-31","value":-4040209400,"profit":false},{"date":"2023-12-31","value":-4265500000,"profit":false}] |
Total Non-Operating Income/Expense | 293.39K | 286.84K | 664.00K | 1.27M | 7.34M | [{"date":"2019-12-31","value":4,"profit":true},{"date":"2020-12-31","value":3.91,"profit":true},{"date":"2021-12-31","value":9.05,"profit":true},{"date":"2022-12-31","value":17.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (24.75M) | (24.75M) | (42.03M) | (39.12M) | (35.31M) | [{"date":"2019-12-31","value":-2475004202,"profit":false},{"date":"2020-12-31","value":-2475004202,"profit":false},{"date":"2021-12-31","value":-4202600000,"profit":false},{"date":"2022-12-31","value":-3911533800,"profit":false},{"date":"2023-12-31","value":-3531500000,"profit":false}] |
Income Taxes | (125.97K) | (125.97K) | 4.00K | 52.88K | - | [{"date":"2019-12-31","value":-238.21,"profit":false},{"date":"2020-12-31","value":-238.21,"profit":false},{"date":"2021-12-31","value":7.56,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (24.62M) | (24.62M) | (42.03M) | (39.17M) | - | [{"date":"2019-12-31","value":-2462407695,"profit":false},{"date":"2020-12-31","value":-2462407695,"profit":false},{"date":"2021-12-31","value":-4203000000,"profit":false},{"date":"2022-12-31","value":-3916821800,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (24.62M) | (42.03M) | (26.58M) | (26.66M) | (35.38M) | [{"date":"2019-12-31","value":-2462407695,"profit":false},{"date":"2020-12-31","value":-4203000000,"profit":false},{"date":"2021-12-31","value":-2658300000,"profit":false},{"date":"2022-12-31","value":-2666500000,"profit":false},{"date":"2023-12-31","value":-3538100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (24.62M) | (24.62M) | (42.03M) | (39.17M) | (35.38M) | [{"date":"2019-12-31","value":-2462407695,"profit":false},{"date":"2020-12-31","value":-2462407695,"profit":false},{"date":"2021-12-31","value":-4203000000,"profit":false},{"date":"2022-12-31","value":-3916821800,"profit":false},{"date":"2023-12-31","value":-3538100000,"profit":false}] |
EPS (Diluted) | (0.07) | (2.05) | (1.01) | (1.07) | (1.40) | [{"date":"2019-12-31","value":-6.62,"profit":false},{"date":"2020-12-31","value":-205,"profit":false},{"date":"2021-12-31","value":-101,"profit":false},{"date":"2022-12-31","value":-107,"profit":false},{"date":"2023-12-31","value":-140,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RCEL | |
---|---|
Current Ratio | 3.73 |
Quick Ratio | 3.37 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RCEL | |
---|---|
ROA (LTM) | -45.37% |
ROE (LTM) | -152.44% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RCEL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.85 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.15 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RCEL | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 5.47 |
P/B | 26.87 |
Price/FCF | NM |
EV/R | 5.49 |
EV/Ebitda | NM |
Avita Medical Ltd (RCEL) share price today is $12.31
Yes, Indians can buy shares of Avita Medical Ltd (RCEL) on Vested. To buy Avita Medical Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RCEL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Avita Medical Ltd (RCEL) via the Vested app. You can start investing in Avita Medical Ltd (RCEL) with a minimum investment of $1.
You can invest in shares of Avita Medical Ltd (RCEL) via Vested in three simple steps:
The 52-week high price of Avita Medical Ltd (RCEL) is $18.93. The 52-week low price of Avita Medical Ltd (RCEL) is $7.51.
The price-to-earnings (P/E) ratio of Avita Medical Ltd (RCEL) is
The price-to-book (P/B) ratio of Avita Medical Ltd (RCEL) is 26.87
The dividend yield of Avita Medical Ltd (RCEL) is 0.00%
The market capitalization of Avita Medical Ltd (RCEL) is $328.51M
The stock symbol (or ticker) of Avita Medical Ltd is RCEL